<?xml version="1.0" encoding="UTF-8" standalone="no"?><rss xmlns:atom="http://www.w3.org/2005/Atom" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:media="http://search.yahoo.com/mrss/" xmlns:slash="http://purl.org/rss/1.0/modules/slash/" xmlns:sy="http://purl.org/rss/1.0/modules/syndication/" xmlns:wfw="http://wellformedweb.org/CommentAPI/" version="2.0">

<channel>
	<title>Medicare reports, fact sheets and explainers from the Kaiser Family Foundation</title>
	<atom:link href="https://www.kff.org/topic/medicare/feed/" rel="self" type="application/rss+xml"/>
	<link>https://www.kff.org/topic/medicare/</link>
	<description></description>
	<lastBuildDate>Thu, 14 May 2026 20:15:34 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=6.8.5</generator>

<image>
	<url>https://www.kff.org/wp-content/uploads/sites/7/2023/04/3976_KFF_favicon_256x256_revised.png?w=32</url>
	<title>Medicare - Research and Data from KFF</title>
	<link>https://www.kff.org/topic/medicare/</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">243654493</site>	<item>
		<title>Medicaid Changes in House and Senate Reconciliation Bills Would Increase Costs for 1.3 Million Low-Income Medicare Beneficiaries</title>
		<link>https://www.kff.org/medicaid/medicaid-changes-in-house-reconciliation-bill-would-increase-costs-for-1-3-million-low-income-medicare-beneficiaries/</link>
		
		<dc:creator><![CDATA[kffmaissm]]></dc:creator>
		<pubDate>Thu, 14 May 2026 20:15:33 +0000</pubDate>
				<category><![CDATA[Medicaid]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Dual Eligible Individuals]]></category>
		<category><![CDATA[Eligibility]]></category>
		<category><![CDATA[Enrollment]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=issue-brief&amp;p=666212</guid>

					<description><![CDATA[On May 22, the House passed a reconciliation bill, the One Big Beautiful Bill Act, which would partially pay to extend expiring tax cuts by cutting Medicaid. The Congressional Budget Office (CBO) estimates that the bill would reduce federal Medicaid spending by $793 billion over ten years and 10.3 million fewer people would be enrolled in Medicaid in 2034, including 1.3 million people with Medicare, otherwise known as “dual-eligible individuals”.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">666212</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2025/06/Reconciliation-bill-would-increase-costs-for-low-income-enrollees_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Reconciliation bill would increase costs for low income enrollees_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2025/06/Reconciliation-bill-would-increase-costs-for-low-income-enrollees_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge</title>
		<link>https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/</link>
					<comments>https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/#respond</comments>
		
		<dc:creator><![CDATA[kffcarenec]]></dc:creator>
		<pubDate>Mon, 11 May 2026 18:12:09 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicaid]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Chronic Diseases]]></category>
		<category><![CDATA[Cost Sharing]]></category>
		<category><![CDATA[Diabetes]]></category>
		<category><![CDATA[Health and Human Services (HHS)]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Obesity]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[This brief describes current coverage of GLP-1s in Medicare and Medicaid, the Centers for Medicare &#38; Medicaid Services’ (CMS) efforts to expand access and lower costs for GLP-1s through temporary demonstration programs including the BALANCE Model, and potential impacts on beneficiaries and program budgets.]]></description>
		
					<wfw:commentRss>https://www.kff.org/medicare/what-to-know-about-the-balance-model-for-glp-1s-in-medicare-and-medicaid/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">705086</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/05/What-to-Know-About-the-BALANCE-Model-for-GLP-1s-in-Medicare-and-Medicaid-and-the-Medicare-GLP-1-Bridge_FI_updated-with-modified-title.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">What to Know About the BALANCE Model for GLP-1s in Medicare and Medicaid and the Medicare GLP-1 Bridge_FI_updated with modified title</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/05/What-to-Know-About-the-BALANCE-Model-for-GLP-1s-in-Medicare-and-Medicaid-and-the-Medicare-GLP-1-Bridge_FI_updated-with-modified-title.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Part D Mail Order Prescription Drugs</title>
		<link>https://www.kff.org/medicare/state-indicator/part-d-mail-order-prescription-drugs/</link>
		
		<dc:creator><![CDATA[kffcleab]]></dc:creator>
		<pubDate>Mon, 04 May 2026 17:56:16 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=state-indicator&amp;p=707999</guid>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">707999</post-id>
	</item>
		<item>
		<title>Part D Retail Prescription Drugs</title>
		<link>https://www.kff.org/medicare/state-indicator/part-d-retail-prescription-drugs/</link>
		
		<dc:creator><![CDATA[kffcleab]]></dc:creator>
		<pubDate>Mon, 04 May 2026 17:44:09 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=state-indicator&amp;p=707994</guid>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">707994</post-id>
	</item>
		<item>
		<title>Changes to the Medicare Advantage Program Enhance Some Consumer Protections But Roll Back Others</title>
		<link>https://www.kff.org/medicare/changes-to-the-medicare-advantage-program-enhance-some-consumer-protections-but-roll-back-others/</link>
		
		<dc:creator><![CDATA[kffalexc]]></dc:creator>
		<pubDate>Fri, 01 May 2026 12:59:23 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Patient and Consumer Protections]]></category>
		<category><![CDATA[Access to Care]]></category>
		<category><![CDATA[Chronic Diseases]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=707709</guid>

					<description><![CDATA[CMS recently finalized policies as part of the 2027 Medicare Advantage final rule that both enhance consumer protections and roll back changes to the Medicare Advantage program that were intended to protect consumers. These changes have gotten less attention than payment issues and changes to the star ratings system, which also affect plan payments, but could have implications for Medicare beneficiaries.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">707709</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/Changes-to-the-Medicare-Advantage-Program-Enhance-Some-Consumer-Protections-But-Roll-Back-Others_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Changes to the Medicare Advantage Program Enhance Some Consumer Protections But Roll Back Others_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/Changes-to-the-Medicare-Advantage-Program-Enhance-Some-Consumer-Protections-But-Roll-Back-Others_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Eligibility for Medicare Savings Programs for Specified Low-Income Medicare Beneficiaries (SLMBs)</title>
		<link>https://www.kff.org/medicare/state-indicator/eligibility-for-medicare-savings-programs-for-specified-low-income-medicare-beneficiaries-slmbs/</link>
		
		<dc:creator><![CDATA[kffalannaw]]></dc:creator>
		<pubDate>Thu, 30 Apr 2026 17:44:39 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[State Health Policy and Data]]></category>
		<guid isPermaLink="false"/>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">177879</post-id>
	</item>
		<item>
		<title>Eligibility for Medicare Savings Programs for Qualified Medicare Beneficiaries (QMBs)</title>
		<link>https://www.kff.org/medicare/state-indicator/eligibility-for-medicare-savings-programs-for-qualified-medicare-beneficiaries-qmbs/</link>
		
		<dc:creator><![CDATA[kffalannaw]]></dc:creator>
		<pubDate>Thu, 30 Apr 2026 17:37:05 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[State Health Policy and Data]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=state-indicator&amp;p=177876</guid>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">177876</post-id>
	</item>
		<item>
		<title>Eligibility for Medicare Savings Programs for Qualifying Individuals (QIs)</title>
		<link>https://www.kff.org/medicare/state-indicator/eligibility-for-medicare-savings-programs-for-qualifying-individuals-qis/</link>
		
		<dc:creator><![CDATA[kffalannaw]]></dc:creator>
		<pubDate>Thu, 30 Apr 2026 17:29:28 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[State Health Policy and Data]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=state-indicator&amp;p=177873</guid>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">177873</post-id>
	</item>
		<item>
		<title>Average Drug Fills and Average Gross Drug Costs Per Medicare Part D Enrollee</title>
		<link>https://www.kff.org/medicare/state-indicator/total-medicare-part-d-spending-per-enrollee/</link>
		
		<dc:creator><![CDATA[kffnatalies]]></dc:creator>
		<pubDate>Thu, 30 Apr 2026 17:29:03 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[State Health Policy and Data]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=state-indicator&amp;p=448612</guid>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">448612</post-id>
	</item>
		<item>
		<title>CMS Extends Medicare’s Short-Term Bridge Program for GLP-1 Obesity Drug Coverage</title>
		<link>https://www.kff.org/quick-take/cms-extends-medicares-short-term-bridge-program-for-glp-1-obesity-drug-coverage/</link>
		
		<dc:creator><![CDATA[kffaeronw]]></dc:creator>
		<pubDate>Thu, 23 Apr 2026 18:42:29 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Federal Budget]]></category>
		<category><![CDATA[Prices]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=quick-take&amp;p=707142</guid>

					<description><![CDATA[Extending the short-term GLP-1 Bridge program is good news for eligible Medicare beneficiaries because it provides the certainty of obesity drug coverage at a $50 copay for a longer duration, but federal spending will also rise by some unknown amount since CMS hasn’t disclosed the projected cost.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">707142</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260423_Quick-Takes_Juliette-Cubanski_Website.jpg?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">260423_Quick-Takes_Juliette-Cubanski_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260423_Quick-Takes_Juliette-Cubanski_Website.jpg?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Medicare Beneficiaries Enrolled in Part D Coverage</title>
		<link>https://www.kff.org/medicare/state-indicator/medicare-beneficiaries-enrolled-in-part-d-coverage/</link>
		
		<dc:creator><![CDATA[kffnatalies]]></dc:creator>
		<pubDate>Fri, 10 Apr 2026 13:19:20 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[State Health Policy and Data]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=state-indicator&amp;p=488230</guid>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">488230</post-id>
	</item>
		<item>
		<title>Number of Medicare Stand-alone Prescription Drug Plans (PDPs)</title>
		<link>https://www.kff.org/medicare/state-indicator/prescription-drug-plans-pdps/</link>
		
		<dc:creator/>
		<pubDate>Fri, 10 Apr 2026 13:02:20 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[State Health Policy and Data]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<guid isPermaLink="false">http://staging.kff.alley.ws/state-indicator/prescription-drug-plans-pdps/</guid>

					<description></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">65295</post-id>
	</item>
		<item>
		<title>Medicare Advantage Insurers Will See Higher Payments as CMS Backs Off a Key Payment Update</title>
		<link>https://www.kff.org/quick-take/medicare-advantage-insurers-will-see-higher-payments-as-cms-backs-off-a-key-payment-update/</link>
		
		<dc:creator><![CDATA[kffcarenec]]></dc:creator>
		<pubDate>Wed, 08 Apr 2026 14:54:03 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Benefits]]></category>
		<category><![CDATA[Enrollment]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Premiums]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=quick-take&amp;p=706299</guid>

					<description><![CDATA[The Trump administration this week backed off a key element of its Medicare Advantage rate proposal, resulting in billions of dollars in additional payments to private insurers. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">706299</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260408_QuickTakes_Jeannie-Fuglesten-Biniek_Website.jpg?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">260408_QuickTakes_Jeannie-Fuglesten-Biniek_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260408_QuickTakes_Jeannie-Fuglesten-Biniek_Website.jpg?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Insurers’ Prior Authorization Data Offers Little Insight Into What Gets Approved or Denied</title>
		<link>https://www.kff.org/quick-take/insurers-prior-authorization-data-offers-little-insight-into-what-gets-approved-or-denied/</link>
		
		<dc:creator><![CDATA[kffcarenec]]></dc:creator>
		<pubDate>Thu, 02 Apr 2026 13:30:27 +0000</pubDate>
				<category><![CDATA[Medicaid]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[ACA Marketplaces]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<category><![CDATA[Prior Authorization]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[Certain insurers must now publicly report specific prior authorization metrics, but the new data offer limited insight, providing no information on what types of services are being approved and denied or why as well as no data on prescription drugs. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">706045</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260402_QuickTakes_Kaye-Pestaina_Website-1.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">260402_QuickTakes_Kaye-Pestaina_Website 1</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/260402_QuickTakes_Kaye-Pestaina_Website-1.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>The New Ideas Conundrum in Health Policy</title>
		<link>https://www.kff.org/from-drew-altman/the-new-ideas-conundrum-in-health-policy/</link>
		
		<dc:creator><![CDATA[kfftammies]]></dc:creator>
		<pubDate>Wed, 01 Apr 2026 13:00:00 +0000</pubDate>
				<category><![CDATA[Affordable Care Act]]></category>
		<category><![CDATA[Elections]]></category>
		<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicaid]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[ACA Marketplaces]]></category>
		<category><![CDATA[Artificial Intelligence]]></category>
		<category><![CDATA[Federal Budget]]></category>
		<category><![CDATA[Politics]]></category>
		<category><![CDATA[Prior Authorization]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=from-drew-altman&amp;p=705696</guid>

					<description><![CDATA[In a new column, President and CEO Dr. Drew Altman writes about the "conundrum of health policy ideas" facing Democrats searching for new proposals because of competing, and complex, priorities: rebuilding Medicaid and the ACA after trillion-dollar cuts, reconstructing federal health agencies, and tackling underlying health care costs, when candidates want simple ideas they can campaign on and voters want their costs to come down. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">705696</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/BTD-Health-Costs-and-Elections-April-2026_Website.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">BTD-Health Costs and Elections-April 2026_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/04/BTD-Health-Costs-and-Elections-April-2026_Website.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Public Opinion on Prescription Drugs and Their Prices</title>
		<link>https://www.kff.org/health-costs/public-opinion-on-prescription-drugs-and-their-prices/</link>
		
		<dc:creator><![CDATA[kffaeronw]]></dc:creator>
		<pubDate>Tue, 31 Mar 2026 12:09:54 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Public Opinion]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<category><![CDATA[Prices]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=poll-findings&amp;p=525491</guid>

					<description><![CDATA[This chart collection draws on recent KFF poll findings to provide an in-depth look at the public's attitudes toward prescription drugs and their prices. Results include the U.S. public’s experiences with prescription drug costs, use of GLP-1 medications, and support for policy solutions.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">525491</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Public-Opinion-on-Prescription-Drugs-and-Their-Prices-FEATURE.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Public Opinion on Prescription Drugs and Their Prices - FEATURE</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Public-Opinion-on-Prescription-Drugs-and-Their-Prices-FEATURE.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>What to Know About Medicare Coverage of Telehealth</title>
		<link>https://www.kff.org/medicare/what-to-know-about-medicare-coverage-of-telehealth/</link>
		
		<dc:creator><![CDATA[kffcarenec]]></dc:creator>
		<pubDate>Thu, 19 Mar 2026 18:23:54 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Access to Care]]></category>
		<category><![CDATA[Administrative Costs]]></category>
		<category><![CDATA[Telehealth]]></category>
		<guid isPermaLink="false"/>

					<description><![CDATA[Congress has repeatedly extended several pandemic-era flexibilities around Medicare coverage of telehealth, but with a few key exceptions most pandemic-era telehealth flexibilities remain temporary. This brief provides answers to key questions about the current scope of Medicare telehealth coverage, including both temporary and permanent changes adopted through legislation and regulation, and policy considerations that lie ahead.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">638147</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/More-than-1-in-10-Traditional-Medicare-Beneficiaries-Used-Telehealth-in-the-First-Half-of-2025_v2.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">More than 1 in 10 Traditional Medicare Beneficiaries Used Telehealth in the First Half of 2025_v2</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/More-than-1-in-10-Traditional-Medicare-Beneficiaries-Used-Telehealth-in-the-First-Half-of-2025_v2.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Are the Tradeoffs from Prior Authorization Worth It? </title>
		<link>https://www.kff.org/from-drew-altman/are-the-tradeoffs-from-prior-authorization-worth-it/</link>
		
		<dc:creator><![CDATA[kffchrisl]]></dc:creator>
		<pubDate>Mon, 16 Mar 2026 16:39:58 +0000</pubDate>
				<category><![CDATA[Health Costs]]></category>
		<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Private Insurance]]></category>
		<category><![CDATA[Access to Care]]></category>
		<category><![CDATA[Administrative Costs]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[Chronic Diseases]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Health Care Utilization]]></category>
		<category><![CDATA[Health System Performance]]></category>
		<category><![CDATA[Managed Care]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<guid isPermaLink="false">https://www.kff.org/?post_type=from-drew-altman&amp;p=704816</guid>

					<description><![CDATA[In his latest column, President and CEO Dr. Drew Altman asks if prior authorization review could be eliminated entirely, discussing how it might be done and the tradeoffs.]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">704816</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/BTD_Prior-Authorization-Review_March-2026_Website.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">BTD_Prior-Authorization-Review_March-2026_Website</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/BTD_Prior-Authorization-Review_March-2026_Website.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Most Medicare Beneficiaries Affected by Plan Terminations in 2025 Have Robust Medicare Advantage Options in 2026</title>
		<link>https://www.kff.org/medicare/most-medicare-beneficiaries-affected-by-plan-terminations-in-2025-have-robust-medicare-advantage-options-in-2026/</link>
					<comments>https://www.kff.org/medicare/most-medicare-beneficiaries-affected-by-plan-terminations-in-2025-have-robust-medicare-advantage-options-in-2026/#respond</comments>
		
		<dc:creator><![CDATA[kffjeanniefb]]></dc:creator>
		<pubDate>Fri, 13 Mar 2026 14:15:40 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Coverage]]></category>
		<category><![CDATA[Enrollment]]></category>
		<category><![CDATA[Health Care Markets]]></category>
		<category><![CDATA[Medicare Advantage]]></category>
		<category><![CDATA[Medigap]]></category>
		<category><![CDATA[Seniors]]></category>
		<category><![CDATA[Traditional Medicare]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=704465</guid>

					<description><![CDATA[Virtually all (98.9%) of the 2.6 million Medicare beneficiaries enrolled in a Medicare Advantage plan that terminated coverage at the end of 2025 have at least one MA-PD available in 2026, including more than two-thirds (68.7%) who have the option of enrolling in a plan sponsored by the same insurer. ]]></description>
		
					<wfw:commentRss>https://www.kff.org/medicare/most-medicare-beneficiaries-affected-by-plan-terminations-in-2025-have-robust-medicare-advantage-options-in-2026/feed/</wfw:commentRss>
			<slash:comments>0</slash:comments>
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">704465</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/MA-plan-terminations-analysis_FI.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">MA plan terminations analysis_FI</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/MA-plan-terminations-analysis_FI.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
		<item>
		<title>Key Facts About Medicare Drug Price Negotiation</title>
		<link>https://www.kff.org/medicare/key-facts-about-medicare-drug-price-negotiation/</link>
		
		<dc:creator><![CDATA[kffjuliettec]]></dc:creator>
		<pubDate>Wed, 11 Mar 2026 19:25:23 +0000</pubDate>
				<category><![CDATA[Medicare]]></category>
		<category><![CDATA[Medicare Part D]]></category>
		<category><![CDATA[Prescription Drugs]]></category>
		<category><![CDATA[Prices]]></category>
		<category><![CDATA[Seniors]]></category>
		<guid isPermaLink="false">https://www.kff.org/?p=704229</guid>

					<description><![CDATA[Under the Medicare Drug Price Negotiation Program, the federal government negotiates prices with drug companies for certain high-cost drugs covered under Medicare Part B and Part D. This brief provides information about several key aspects of the Medicare drug price negotiation program, with a focus on the 2028 implementation year. ]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">704229</post-id>
		<media:content medium="image" url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Key-Facts-About-Medicare-Drug-Price-Negotiation.png?w=150&amp;h=150&amp;crop=1">
			<media:title type="html">Key Facts About Medicare Drug Price Negotiation</media:title>
			<media:description type="html"/>
			<media:thumbnail url="https://www.kff.org/wp-content/uploads/sites/7/2026/03/Key-Facts-About-Medicare-Drug-Price-Negotiation.png?w=150&amp;h=150&amp;crop=1"/>
		</media:content>
	</item>
	</channel>
</rss>